Binghe Xu Selected Research

Binghe Xu Research Topics

Disease

194	Breast Neoplasms (Breast Cancer) 03/2024 - 11/2007
83	Neoplasms (Cancer) 04/2024 - 05/2008
51	Triple Negative Breast Neoplasms 02/2024 - 01/2013
22	Disease Progression 12/2023 - 11/2007
21	Neutropenia 05/2023 - 11/2007
19	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2012
7	Leukopenia 12/2023 - 05/2015
7	Diarrhea 03/2021 - 06/2013
6	Peripheral Nervous System Diseases (PNS Diseases) 02/2023 - 01/2017
6	Lymphatic Metastasis 01/2021 - 10/2010
6	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2009
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2014 - 11/2002
5	Hand-Foot Syndrome 03/2021 - 10/2019
5	Stomach Neoplasms (Stomach Cancer) 01/2017 - 03/2015
5	Lung Neoplasms (Lung Cancer) 01/2014 - 05/2008
4	Pneumonia (Pneumonitis) 01/2023 - 01/2018
4	Febrile Neutropenia 11/2022 - 05/2014
4	Carcinogenesis 05/2021 - 05/2008
4	Exanthema (Rash) 12/2020 - 09/2014
4	Nausea 10/2019 - 09/2017
3	Thrombocytopenia (Thrombopenia) 05/2023 - 07/2021
3	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2023 - 01/2022
3	Cardiotoxicity 01/2022 - 12/2014
3	Stomatitis 01/2022 - 05/2014
3	Hypertension (High Blood Pressure) 03/2021 - 05/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 03/2021 - 12/2018
3	Circulating Neoplastic Cells 01/2021 - 10/2016
3	Esophageal Neoplasms (Esophageal Cancer) 01/2019 - 03/2015
3	Pathologic Complete Response 01/2019 - 04/2016
3	Fatigue 01/2018 - 11/2007
2	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 06/2023

Drug/Important Bio-Agent (IBA)

46	Hormones (Hormone)IBA 03/2024 - 01/2011
37	Trastuzumab (Herceptin)FDA Link 10/2023 - 01/2013
33	human ERBB2 proteinIBA 03/2024 - 09/2012
31	AnthracyclinesIBA 01/2022 - 11/2007
28	Capecitabine (Xeloda)FDA Link 12/2023 - 11/2007
25	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 12/2010
23	ErbB Receptors (EGF Receptor)IBA 02/2024 - 06/2013
22	taxaneIBA 02/2023 - 11/2007
19	Biomarkers (Surrogate Marker)IBA 11/2023 - 05/2008
19	Taxoids (Taxanes)IBA 02/2023 - 11/2007
16	PlatinumIBA 01/2023 - 05/2008
13	pyrotinibIBA 12/2023 - 09/2017
13	Vinorelbine (Navelbine)FDA LinkGeneric 01/2023 - 01/2010
13	Epirubicin (Ellence)FDA LinkGeneric 01/2023 - 09/2012
12	Docetaxel (Taxotere)FDA Link 10/2023 - 05/2014
12	Estrogen ReceptorsIBA 12/2022 - 01/2013
12	Lapatinib (GW572016)FDA Link 01/2021 - 01/2013
11	Progesterone Receptors (Progesterone Receptor)IBA 10/2022 - 01/2013
10	Aromatase InhibitorsIBA 03/2024 - 01/2011
10	Phenobarbital (Luminal)FDA Link 02/2022 - 12/2013
9	Fulvestrant (Faslodex)FDA Link 08/2023 - 01/2011
9	Indicators and Reagents (Reagents)IBA 02/2023 - 10/2016
9	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2008
8	Carboplatin (JM8)FDA LinkGeneric 01/2024 - 07/2011
8	Circulating Tumor DNAIBA 11/2023 - 01/2017
7	Letrozole (Femara)FDA LinkGeneric 03/2024 - 01/2011
7	exemestane (Aromasin)FDA Link 08/2023 - 04/2014
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2023 - 09/2012
6	Tyrosine Kinase InhibitorsIBA 02/2024 - 04/2014
6	Everolimus FDA Link 12/2023 - 05/2014
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2008
6	ixabepilone (BMS 247550)FDA Link 08/2012 - 11/2007
5	Phosphotransferases (Kinase)IBA 01/2024 - 05/2017
5	apatinibIBA 01/2024 - 10/2014
5	Immune Checkpoint InhibitorsIBA 11/2023 - 03/2016
5	pertuzumabIBA 02/2023 - 01/2019
5	olaparibIBA 01/2023 - 10/2017
5	Epidermal Growth Factor (EGF)IBA 01/2023 - 04/2016
5	camrelizumabIBA 02/2019 - 01/2018
4	Anastrozole (Arimidex)FDA LinkGeneric 03/2024 - 01/2011
4	TOR Serine-Threonine KinasesIBA 12/2023 - 05/2019
4	dalpiciclibIBA 01/2023 - 04/2021
4	Tamoxifen FDA LinkGeneric 12/2022 - 01/2018
4	Cyclin-Dependent Kinase 4IBA 11/2022 - 04/2021
4	MicroRNAs (MicroRNA)IBA 01/2018 - 08/2011
4	Cisplatin (Platino)FDA LinkGeneric 12/2015 - 10/2008
4	Gemcitabine FDA Link 12/2014 - 12/2010
3	130-nm albumin-bound paclitaxelIBA 02/2024 - 11/2022
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 12/2023 - 11/2016
3	anlotinibIBA 11/2023 - 03/2021
3	Histone Deacetylase InhibitorsIBA 08/2023 - 01/2021
3	MTOR InhibitorsIBA 08/2023 - 12/2020
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 06/2023 - 01/2016
3	Ado-Trastuzumab EmtansineIBA 01/2023 - 07/2021
3	trastuzumab deruxtecanIBA 01/2023 - 01/2022
3	eribulin FDA Link 01/2023 - 01/2019
3	palbociclibIBA 11/2022 - 01/2021
3	neratinibIBA 10/2019 - 11/2014
2	ribociclibIBA 03/2024 - 01/2023
2	Cell-Free Nucleic AcidsIBA 03/2024 - 10/2020
2	Mechanistic Target of Rapamycin Complex 1IBA 12/2023 - 01/2021
2	Alanine Transaminase (SGPT)IBA 12/2023 - 11/2016

Therapy/Procedure

89	Therapeutics 04/2024 - 11/2002
75	Drug Therapy (Chemotherapy) 06/2023 - 05/2008
22	Neoadjuvant Therapy 01/2024 - 09/2012
17	Adjuvant Chemotherapy 02/2023 - 01/2015
8	Immunotherapy 11/2023 - 01/2019
6	Radiotherapy 01/2023 - 10/2010
3	Aftercare (After-Treatment) 01/2022 - 11/2014